Alexion Reports Third Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q
October 29, 2015 1:14 PM EDTCowen reiterated an Outperform rating and $216.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's 3Q earnings report. Alexion reported Q3 Soliris sales of $665.4MM vs. consensus $666MME and nonGAAP EPS of $1.16 vs. $1.01E.
Analyst Eric Schmidt commented, "Alexion reported Q3... More
Alexion Pharma (ALXN) Tops Q3 EPS by 15c; Guides Above Views
October 29, 2015 7:52 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.16, $0.15 better than the analyst estimate of $1.01. Revenue for the quarter came in at $666.6 million versus the consensus estimate of $668.33 million.
Alexion Pharma sees FY2015 EPS of $4.92-$4.97, versus the consensus of $4.82.
The third... More
